Cipla shares drop 2% after US FDA approves rival's generic Advair inhaler. Aurobindo Pharma's Lannett acquisition may raise US revenue by $30-40 million Cipla seeks FDA approval for generic Advair, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results